Clinical Trials

Text Size A A

E-Mail to a Friend






secret  Click to Play Audio


Colorectal Cancer

 

Capecitabine and Celecoxib w/wo Radiation Therapy for Colorectal Cancer Patients Previously Treated With Fluorouracil (ADAPT - 7707)
A Phase II Trial of Maintenance ADAPT Therapy With Capecitabine and Celecoxib in Patients With Metastatic Colorectal Cancer

Investigator: Edward Lin, MD;   Conditions: Recurrent Colon Cancer, Recurrent Rectal Cancer;    Status: Recruiting;   Study ID: NCT01729923

TheraSphere® Metastatic Colorectal Carcinoma of the Liver (7627 - TS-102)
A Phase III Clinical Trial Evaluating TheraSphere® in Patients with Metastatic Colorectal Carcinoma of the Liver Who Have Failed First Line Chemotherapy

Investigator: William Harris;   Conditions: Colorectal Cancer;    Status: Recruiting;   Study ID: NCT01483027

PARP Inhibitor ABT-888 with Carboplatin & Gemcitabline (M10-758) (UW09039)
A Phase 1 Study of ABT-888 (Veliparib) in Combination With Carboplatin (Paraplatin) and Gemcitabline (Gemzar) in Subjects With Advanced Solid Tumors

Investigator: Heidi J. Gray, MD;   Conditions: Advanced Solid Tumors;    Status: Closed;   Study ID: NCT01063816

MDX-1105 for Advanced or Recurrent Cancer (UW08038)
A Phase 1, Open-label, Dose-escalation, Multidose Study of MDX-1105 Administered Every 14 Days in Subjects With Selected Advanced or Recurrent Solid Tumors

Investigator: Scott S. Tykodi, MD, PhD;   Conditions: Renal Cell Carcinoma, Non-small Cell Lung Cancer, Malignant Melanoma, Epithelial Ovarian Cancer;    Status: Recruiting;   Study ID: NCT00729664

GS-6624 With FOLFIRI as Second Line Treatment for Colorectal Cancer (11053)
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GS-6624 Combined With FOLFIRI as Second Line Treatment for Metastatic KRAS Mutant Colorectal Adenocarcinoma That Has Progressed Following a First Line Oxaliplatin- and Fluoropyrimidine-Containing Regimen.

Investigator: Andrew Coveler, MD;   Conditions: Colorectal Cancer;    Status: Recruiting;   Study ID: NCT01479465

Dalotuzumab + Irinotecan vs Cetuximab +Irinotecan for Metastatic Rectal Cancers (20111765)
A Phase IIA Open Label, Adaptive, Randomized Clinical Trial of Dalotuzumab (MK-0646) Treatment in Combination with Irinotecan Versus Cetuximab and Irinotecan for Patients with Metastatic Rectal Cancers (mRC) Expressing High IGF-1/Low IGF-2 Levels

Investigator: Edward Lin, MD;   Conditions: Colon Cancer; Rectal Cancer; Solid Tumors;    Status: Closed;   Study ID: NCT01609231

Chemotherapy or Chemotherapy + Radiation for Rectal Cancer Patients Undergoing Surgery (The PROSPECT Trial)
A Phase II/III Trial of Neoadjuvant FOLFOX, With Selective Use of Combined Modality Chemoradiation Versus Preoperative Combined Modality Chemoradiation for Locally Advanced Rectal Cancer Patients Undergoing Low Anterior Resection With Total Mesorectal Excision

Investigator: Veena Shankaran, MD;   Conditions: Colorectal Cancer;    Status: Recruiting;   Study ID: NCT01515787

FOLFOXIRI/Avastin Versus FOLFOX/Avastin for Metastatic Colorectal Cancer-STEAM (13010)
STEAM: (Sequential Triplet And Avastin Maintenance): Folfoxiri/Bevacizumab Regimens (Concurrent And Sequential) Vs. Folfox/Bevacizumab In First-Line Metastatic Colorectal Cancer

Investigator: Gabriela Chiorean, MD;   Conditions: Colorectal Cancer;    Status: Recruiting;   Study ID: NCT01765582

MPDL3280A + Cobimetinib for Locally Advanced or Metastatic Cancer
A Phase 1b Study of the Safety and Pharmacology of MPDL3280A Administered With Cobimetinib in Patients With Locally Advanced or Metastatic Solid Tumors

Investigator: Laura Chow, MD;   Conditions: Neoplasms;    Status: Recruiting;   Study ID: NCT01988896

MABp1 for Patients w/ Colorectal Cancer Who Are Losing Weight
A Pivotal Phase III Study to Evaluate Overall Survival Using MABp1 as a Monotherapy in Metastatic Colorectal Cancer Patients With Cachexia

Investigator: Andrew L. Coveler, MD;   Conditions: Metastatic Colorectal Cancer;    Status: Recruiting;   Study ID: NCT01767857